Tag: Presentations
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium
At this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (TACE) therapy in combination strategy with lenvatinib (TACTICS-L) in patients with unresectable hepatocellular carcinoma (uHCC) in Japan (Abstract No: 417), as well as research updates on the Phase IV Study (STELLAR) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (Abstract No: TPS485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uHCC (investigator-initiated study in Japan, Abstract No: 458), will be presented.
In addition, trial-in-progress (TiP) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), include the Phase III LEAP-014 Study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (Abstract No: TPS367), Phase III LEAP-015 Study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (Abstract No: TPS369), Phase III Study LEAP-012 of the combination plus TACE in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (Abstract No: TPS494), and Phase II Study of the combination plus belzutifan in patients with advanced solid tumors (Abstract No: TPS669).
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
About the Merck & Co., Inc., Kenilworth, N.J., U.S.A. and Eisai Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A.
In addition to ongoing clinical studies evaluating the LENVIMA plus KEYTRUDA combination across several different tumor types, the companies have jointly initiated new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.
Eisai's Focus on Cancer
Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022.
A Deep Look Into 13 Data Scientist Roles and Their Responsibilities
Intel and Nvidia just dunked on Apple’s M1 Max. Should you believe the hype?
When Apple finally released its M1 Max processor in October, the Internet predictably saw dark days for PC laptops. Some even felt bad for PC laptop makers being uncompetitive with the MacBook Pro for perhaps “years.” Those predictions may have to be retuned a bit now that Intel and Nvidia have both come out swinging at Apple, however.
Nvidia was the first to step on Apple's sneakers when it announced its new GeForce RTX 3070 Ti and GeForce RTX 3080 Ti Laptop GPUs. Nvidia casually compared not just its newest GeForce RTX 3080 Ti Laptop GPU against Apple's fastest M1 Max, but also the far more pedestrian GeForce RTX 3060 Laptop GPU using Autodesk Arnold, Blender, Chaos V-Ray, OctaneRender and Redshift.
As you can see from the comparison with the MacBook Pro 16's M1 Max, both the new GeForce flagship and the far blander RTX 3060 Laptop GPU simply crush the M1 Max. And by crush, we mean crush, because when a GeForce RTX 3080 Ti Laptop GPU takes 10 minutes to perform a render and a GeForce RTX 3060 Laptop GPU takes 22 minutes using Autodesk Arnold, versus 78 minutes for the M1 Max, it's a beat-down. That's an 87 percent decrease in rendering time for the RTX 3080 Ti vs. the M1 Max, and a 78 percent advantage for the RTX 3060. That's a shellacking no matter how you count it for working creators, but it should be pointed out that many of these apps have long been optimized for Nvidia's GPUs, giving GeForce a home field advantage.
Nvidia
For example, it's not clear if the testing Nvidia did for Blender Cycles used the version that's currently being ported to Apple's M1 and Metal API. We'd guess not since the presentation would have been based on numbers likely prepared well before CES 2022 to meet approval for public dissemination. With Blender support still in pre-beta stage, it's highly doubtful the Blender score is running an alpha version.
So is it fair if Nvidia shows off a stack of benchmarks arguably optimized for its GPU versus the unknown quantity of M1 Max support? It depends.
If your idea of a good time is to get into a yelling match on Twitter while wearing an Apple team jersey over the “unfairness” of Nvidia's results, then it's definitely not fair. If you're a working professional who gets paid to shovel pixels in Autodesk Arnold, Blender, V-Ray, OctaneRender, or Redshift, then it's most certainly a fair test, since the only thing you probably care about is how fast your hardware can make you money.
Intel steps up too
After Nvidia poked Apple in the nose a few times, Intel jumped into the ring later that morning by saying that its new 12th-gen “Alder Lake” laptop CPUs are faster than not only its older 11th-gen Tiger Lake H CPUs and AMD's Ryzen 9 5900HX, but also Apple's M1 Max. So yes, as the slide below says, the fastest mobile processor. Ever.
Intel
What's that based on? Fortunately, responsible companies show their homework as Intel did. In fact, Intel shows way more of its work than Nvidia did in its video, which publishes the results, but no information about how it tested the laptops.
Intel says its performance results for the Apple M1 Max is estimated based on: “public statements made by Apple on 10/18/2021 and measurements on Apple M1 Max 16″ 64GB RAM Model A2485. The metric used is the geometric mean of an n-copy SPECrate run of the C/C++ integer benchmarks in SPEC CPU 2017.”
For the uninitiated, SPEC is published by Standard Performance Evaluation Corporation, an industry group that has come together to create various agreed-upon tests and proclaims itself a “beacon of truth for 30 years.” Members include a who's who of tech companies including AMD, Apple, Intel, and Nvidia. You're typically required to publish much of the fine print, including wh at was used to compile the executables for the test too.
In Intel's case, it said it used ICC for the Windows laptops and Apple's Xcode 13.1 for the M1 Max. To its credit (although some would say it's just to avoid further Imperial entanglements), Intel discloses far more details on how it achieved its claim here.
Intel
Still, the upshot of Intel's tests says that even at 28 watts or so of power consumption, it's easily outperforming the M1 Max in a test even Apple has signed onto. As you push the wattage envelope of the Core i9-12900HK you're looking at perhaps near 45 percent more performance than that M1 Max.
So, what should you believe? One problem with SPEC benchmarks, though sometimes based on actual application code, is the lack of relatability for consumers. They can be useful for computer science students arguing in the quad, but for most people they're pretty esoteric. We'd probably want to see something we can relate to before determining if and how much of a beat down the new 12th-gen Alder Lake gives the M1 Max. It's very hard to argue against a test published by a benchmarking group even Apple is a member of though.
MSI GE76 Raider
And it's good Intel published its homework. We wish Nvidia would have said a little more about how it tested the laptops against the Apple M1 Max—did the workloads include ray tracing features that GeForce GPUs pack dedicated hardware for? But it's hard to complain about what Nvidia did when Apple has been publishing results like the one below. This is a benchmark result Apple showed off for the M1 Max's launch and, frankly, we still have no idea what Apple based it on. The dark gray line represents MSI's killer GE76 Raider gaming laptop that's actually—to Apple's credit—displayed as being faster than the M1 Max. The lighter gray line is a Razer Blade Advanced, which is slightly slower than the M1 Max. Both are outfitted with a GeForce RTX 3080 Laptop GPUs.
Apple
The M1 Max may lose or come close to Nvidia's GPUs in raw performance, but Apple's real victory is its power consumption. Apple's M1 Max and its TSMC 5nm process is indeed impressive for the power it consumes. At the same time, just what the hell was Apple testing? We have no doubt the M1 Max is indeed efficient, but of the three “our bars are longer” presentations, Apple's is the thinnest on actual details and mostly leaves you wondering just how it determined what it did. If you're concerned over Nvidia or Intel being fair, you should be even more concerned about Apple's claims.
In the end, consumers should always take any vendor's claims with a grain of salt. Wait for independent reviews using tests that relate to what you actually do with your laptop before deciding what to buy.
Let’s Play! Raising the Stakes for Threat Modeling With Card Games
How Bitcoin 2021 Redefined The Importance Of In-Person Celebration
Needham & Company to Host the 24th Annual Needham Growth Conference, January 10-14, 2022
International Conference on “MSMEs: Legislative and Regulatory Challenges” (UNCITRAL and Indian Perspective)
CJ’s five favorite games of 2021 that Destructoid didn’t review
Because you can’t review them all Anybody who says that 2021 was a lackluster year for gaming must have been...
The post CJ’s five favorite games of 2021 that Destructoid didn’t review appeared first on Destructoid.
Event: Insuring Cannabis Summit Presented By The Insurance Journal
Deliver a Killer Presentation in Data Science Interviews
DISCO to Present at Needham Growth Conference
AUSTIN, Texas–(BUSINESS WIRE)–Legal technology leader CS Disco, Inc. (“DISCO”) (NYSE: LAW) today announced that its Chief Executive Officer, Kiwi Camara, and Chief Financial Officer, Michael Lafair, will present at the Needham Growth Conference. Date: Tuesday, January 11, 2022 Time: 2:00 p.m. ET (1:00 p.m. CT) Webcast: Events and Presentations at ir.csdisco.com; an archived replay will […]
The post DISCO to Present at Needham Growth Conference appeared first on Fintech News.
NiftyAgenda Final Lineup Includes 20 Demos, NFT Gallery Showing and Press Conference on Underdogs and Female Empowerment Featuring NFT Platform Banned from CES
LAS VEGAS - January 6, 2022 - CoinAgenda (www.coinagenda.com), the premier global conference series connecting blockchain and cryptocurrency investors with startups since 2014, today is launching its newest NFT-focused event, NiftyAgenda, with an exclusive launch party on January 6 from 5-11 pm in Las Vegas, following CES®, the largest Consumer Electronics Show in the world. All NFT creators, innovators, buyers, and media are invited.
NFT mainstream popularity exploded in 2021, starting in Q1 when Beeple's Everydays: The First 5000s, sold in auction for $69 million, bringing rise for artists to take digital ownership and compensation over their art. With the sales of NFTs expected to exceed $20 billion by the end of 2021, NiftyAgenda will kick off with presentations and a meet-and-greet from the leaders behind the hottest upcoming NFT drops.
Presenters include:
Hot Drops, the first inclusive adult NFT marketplace disrupting how creators and fans connect with next-gen content.
Fearless Girl, the iconic statue on Wall Street, which is issuing a series of NFTs to fight lawsuit by a big bank to seize control of her copyrights.
Starter Capital, the leading launchpad, incubator, and investor network for Polygon, Ethereum, Fantom, Avalanche, BSC, which is partnering with the OpenDao initiative to decentralize OpenSea.
NFTY, a blockchain studio and incubator for the next generation of NFT technology.
SDG Exchange, a global sustainability marketplace dedicated to reversing climate change one transaction at a time.
Echo Labs, a space for artists of all kinds to get their voices heard and their distinct point of view and missions noticed.
Icecap, a Blockchain-Based Diamond NFT Marketplace.
RAIR TECH, a blockchain-based digital rights management platform that uses NFTs to gate access to streaming content.
Tradery Capital, an AI-powered asset manager for Coinbase customers.
Pixel Bird, a NFT collection of pixelated birds, the result of the evolution of a group of dinosaurs that lived hundreds of years ago.
Frogland, a hand-drawn series of 10,000 generative NFTs, with each frog being entitled to a LillyPAD, or Personal Access Domain, with Frogland, the central most founding district of the metaverse.
On1 Force, a collection of 7,777 generative side-profile characters with over 100 hand-drawn features fighting for their existence.
A List Apes, a NFT project featuring a unified community that represents each unique person and makes them feel comfortable with their individuality of character, appearance, and principles.
Following presentations by NFT creators and analysts will be an immersive digital gallery showcasing the NFT creators' newest drops and a concert by Think:X, featuring legendary Pink Floyd sax player, and NFT creator Scott Page, and Jane's Addiction drummer, Stephen Perkins. This all-star line up will perform “Beyond the Wall,” an exploration of the music of Pink Floyd, for a Think Floyd experience. The concert will simultaneously happen with NFT demonstrations and videos in the background, a full bar and heavy hors d'oeuvres. NiftyAgenda is being held at two iconic former celebrity estates ten minutes from the Strip; location details will be given with ticket purchase. Space is limited.
NiftyAgenda tickets are available for $299 and include the meet-and-greet segment, NFT gallery showcase, and Think:X concert. CES accredited media will be allowed in at no cost upon independent verification of credentials.
For more information, please contact contact@coinagenda.com.
ABOUT NIFTYAGENDA
NiftyAgenda brings together NFT creators, innovators, buyers and media. NiftyAgenda is the newest conference from CoinAgenda, which has been producing high-end crypto investor events globally since 2014.
ABOUT COINAGENDA
Now in its eighth year, CoinAgenda is the leading global conference series connecting professional investors, traders, family offices and digital currency funds with top entrepreneurs in the blockchain and cryptocurrency sectors. CoinAgenda is an experience that allows all attendees to meet, mingle, and get to know the leading thought leaders, entrepreneurs and investors in the sector, including memorable parties at unique locations.
Disclaimer: Consumer Electronics Show”, "CES,” “CES®” and “International CES®” are registered trademarks of the Consumer Electronics Association. NiftyAgenda at CES 2022 is not affiliated with or endorsed by CES or the Consumer Electronics Association.